SB-284851-BT

Cat. No.: HY-136794

CAS No.: 219769-23-0

Molecular Formula: $C_{26}H_{26}FN_5O$

Molecular Weight: 443.52

Target: p38 MAPK; Epigenetic Reader Domain

Pathway: MAPK/ERK Pathway; Epigenetics

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	SB-284851-BT is an inhibitor of BRD4/p38α/BRDT. SB-284851-BT inhibits BRD4-BD1 (IC_{50}=1.7 μM), p38α (K_d=0.47 nM), BRDT (1) (IC_{50}=18 μM) and BRD4 (1)(IC_{50}=3.7 μM). SB-284851-BT reduces IL-8 production by inhibiting p38α, as well as inhibiting BRD4 to down-regulates c-Myc and NF-κB gene pathways in cancer. SB-284851-BT can combined with the bromine domain and extra terminal (BET)[1][2].			
IC_{50} & Target	p38α 0.47 nM (Kd)	BRD4-BD1 1.7 μM (IC_{50})	BRDT (1) 18 μM (IC_{50})	BRD4(1) 3.7 μM (IC_{50})

REFERENCES

[1]. Divakaran A, et al. Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor. J Med Chem. 2018 Oct 25;61(20):9316-9334.

[2]. Jin W, et al. Dual-target inhibitors of bromodomain-containing protein 4 (BRD4) in cancer therapy: Current situation and future directions. Drug Discov Today. 2022 Jan;27(1):246-256.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA